Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,451,942 | 9,883,777 | 909,359 | 905,779 | 1,835,978 |
| Marketable Securities | 0 | 16,491 | 1,347,776 | 1,364,539 | 1,175,321 |
| Receivables | 2,163,659 | 1,951,167 | 1,867,092 | 1,938,645 | 1,801,212 |
| Inventories | 1,418,033 | 1,389,983 | 1,337,751 | 1,321,615 | 1,304,457 |
| Income taxes - deferred | 193,938 | 208,155 | 283,856 | 277,611 | 277,835 |
| Other current assets | 175,629 | 5 | 115,643 | 85,018 | 96,081 |
| TOTAL | $5,826,532 | $13,918,790 | $6,147,267 | $6,219,045 | $6,851,132 |
| Non-Current Assets | |||||
| PPE Net | 782,867 | 774,406 | 761,190 | 721,884 | 703,794 |
| Investments And Advances | 48,168 | 63,704 | 3,224,981 | 3,228,994 | 3,344,999 |
| Intangibles | 12,845,949 | 2,066,966 | 2,111,003 | 2,128,410 | 1,629,971 |
| Other Non-Current Assets | 446,866 | 479,273 | 395,457 | 395,807 | 457,458 |
| TOTAL | $14,123,850 | $3,384,349 | $6,492,631 | $6,475,095 | $6,136,222 |
| Total Assets | $19,950,390 | $17,303,130 | $12,639,900 | $12,694,140 | $12,987,350 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,351,573 | 1,572 | 1,587 | 7,345 | 653,093 |
| Accounts payable and accrued liabilities | 1,339,257 | 1,206,052 | 1,063,723 | 1,102,319 | 981,631 |
| Accrued Expenses | 789,329 | 720,789 | 561,464 | 514,273 | 467,638 |
| TOTAL | $4,187,904 | $2,514,790 | $2,224,431 | $2,310,841 | $2,768,765 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,231,237 | 7,753,470 | 4,030,532 | 4,027,237 | 3,899,928 |
| Deferred Revenues | 100,191 | 74,665 | 68,673 | 63,243 | 97,373 |
| Other Non-Current Liabilities | 145,080 | 139,041 | 120,611 | 120,793 | 116,863 |
| TOTAL | $8,398,398 | $7,920,995 | $4,182,261 | $4,171,968 | $4,043,228 |
| Total Liabilities | $12,586,300 | $10,435,780 | $6,406,692 | $6,482,809 | $6,811,993 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,514,644 | 1,514,631 | 1,502,278 | 1,542,910 | 1,574,109 |
| Common Shares | 758 | 753 | 757 | 777 | 791 |
| Retained earnings | 2,178,639 | 1,776,760 | 1,321,796 | 1,395,908 | 1,320,335 |
| Other shareholders' equity | 84,063 | 186,693 | 100,901 | 31,207 | 127,926 |
| TOTAL | $7,364,084 | $6,867,349 | $6,233,206 | $6,211,331 | $6,175,361 |
| Total Liabilities And Equity | $19,950,384 | $17,303,129 | $12,639,898 | $12,694,140 | $12,987,354 |